To compare triflusal and aspirin in the secondary prevention of ischemic stroke.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Triflusal (Disgren)Drug
Other Names: Disgren® Intervention Desc: Antiplatelet agent structurally related to aspirin
Randomized, double-blind, multicenter pilot trial of 431 patients.
Patients were randomized to receive aspirin (325 mg/day) or trifusal (600 mg/day) for a median of 586 days.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Vascular death, non-fatal stroke, non-fatal MI, or major bleeding.|
|Secondary||Non-vascular death, non-severe hemorrhage, systemic thromboembolism.|